Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Monotherapy in Third-Line Metastatic Gastric Cancer
NCT02662959Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Apr 2015
- Primary completion
- May 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC), sponsored by Fudan University. Primary endpoint: Overall Survival at 1 year. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02662959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662959.